Array BioPharma will soon be entering a pivotal trial for its wholly owned blood cancer drug and investors should know its outlook by the end of 2014, says the company's CEO Ron Squarer. Array is also partnering with AstraZeneca and Novartis on a number of other cancer drugs with trials soon getting underway that could transform the company by year end. Squarer says Array is superior at smaller, faster hematology studies, while partnerships work better for larger projects, and he is not giving away the store when teaming up with the likes of Celgene.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.